All In MedTech

Device Trial Radar · NCT07927478

Transcutaneous Auricular Vagal Neuromodulation Therapy (AVNT™) in Chronic Kidney Disease Autonomic Dysfunction

Feasibility and Preliminary Efficacy of Transcutaneous Auricular Vagal Neuromodulation Therapy (AVNT™) in Chronic Kidney Disease Autonomic Dysfunction: A Randomized, Sham-Controlled Pilot Trial (Parasym-CKD)

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 10, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Factorial
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this pilot study is to establish the feasibility of home-based Auricular Vagal Neuromodulation Therapy (AVNT™) in Chronic Kidney Disease (CKD) patients, generate preliminary efficacy data on autonomic function outcomes, and explore whether timing variation influences treatment response.

Conditions

  • Chronic Kidney Disease (CKD) Stages G3 to G5

Interventions

  • Auricular Vagal Neuromodulation Therapy (AVNT™)Device

    The device consists of a handheld stimulation unit (\~2 inches) connected to a tragus earpiece electrode (worn like an in-ear headphone, removed after each session). Participants will undergo AVNT™ at home once daily for 60 minutes either in the morning at 7am or in the evening at 7pm at a pulse width of 250 μs, frequency of 20 Hz, and comfortable, patient-titrated intensity based on personalized perceptual thresholds.

  • Sham-deviceDevice

    The device is equipped with a "ramp-down sham mode". In this mode, no electrical stimulation will occur for the remainder of the session and participant intensity adjustments are disabled. Participants will use the sham-device at home once daily for 60 minutes either in the morning at 7am or in the evening at 7pm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Orthostatic Heart Rate ResponseTime frame: Week 0, Week 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.